<DOC>
	<DOCNO>NCT02173678</DOCNO>
	<brief_summary>Study assess safety tolerability COMBIVENT® hydrofluoroalkane ( HFA ) compare COMBIVENT® chlorofluorocarbon ( CFC ) placebo HFA single repetitive dose healthy male female subject</brief_summary>
	<brief_title>Safety Tolerability COMBIVENT® HFA Compared COMBIVENT® CFC Placebo HFA Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy males/females Age range 21 50 year within 20 % normal weight ( BrocaIndex ) All female volunteer must use safe contraception ( i.e . oral contraceptive , intrauterine device ; sterilise ) must negative urine pregnancy test All subject must negative hepatitis B , C HIV test well negative drug screen Prior admission treatment give his/her inform consent ( accordance Good Clinical Practice local legislation ) writing , subject his/her medical history take receive complete medical examination ( incl . blood pressure pulse rate measurement ) well 12lead ECG within 14 day first administration test drug . Haematopoietic , hepatic renal function test carry laboratory . The subject fast 12 hour collection specimens laboratory parameter Currently nonsmoking ( smoke free &gt; = one year &lt; =5 pack year smoke history ) Normal spirometry evidence baseline FEV1 &gt; = 90 % predict normal value age , height sex Predicted normal value calculate accord European Community Steel Coal ( ECCS ) Ability adequately use inhalation aerosol device Ability perform technically satisfactory pulmonary function test Volunteers exclude study result medical examination laboratory test ( especially serum glutamate oxaloacetate transaminase ( SGOT ) &gt; 2fold upper normal range , serum glutamate pyruvate transaminase ( SGPT ) &gt; 1.5 fold upper normal range ) judge investigator differ significantly normal clinical value Volunteers eosinophil count &gt; = 600/mm³ . A repeat eosinophil count conduct subject Volunteers serum potassium value &gt; + 10 % outside normal range Volunteers known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic immunological hormonal disorder Volunteers diseases central nervous system ( epilepsy ) psychiatric disorder Volunteers know history orthostatic hypotension , faint spell blackouts Volunteers chronic relevant acute infection Volunteers upper respiratory tract infection past six week prior screen visit screen visit first test day Volunteers history asthma allergic rhinitis Volunteers history allergy/hypersensitivity ( include drug allergy , especially anticholinergic betaagonist agent ) deem relevant trial judge investigator Volunteers know narrowangle glaucoma Volunteers disturb micturition Volunteers take drug long halflife ( &gt; = 24 hour ) within ten halflives respective drug enrolment study Volunteers receive concomitant therapy , include counter medication ( include vitamin , supplement and/or nonsteroidal antiinflammatory drug ; exclude oral depository contraceptive ) within one week screen visit Volunteers participate another study investigational drug within last two month precede study Volunteers drink 40g alcohol per day Volunteers dependent drug Volunteers donate blood ( &gt; = 100 ml ) within last four week Volunteers participate excessive physical activity ( e.g . competitive sport ) within last week study Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e . contraceptive , intrauterine device , sterilise ) Volunteers significant tremor measure screen visit Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>